Hepatitis
From the Journals
HBV: Surface antigen titer and ALT predict seroconversion
In patients with hepatitis B virus infection, surface antigen titer and alanine aminotransferase level may independently predict spontaneous...
From the Journals
Occult HCV infection is correlated to unfavorable genotypes in hemophilia patients
Unfavorable interferon gentoypes were correlated to occult HCV infection in paitents with hemophilia.
Latest News
HCV a risk in HIV-negative MSM who use PrEP
HIV-negative MSM on PrEP are at risk for HCV-infection, with risk-factors similar to those in HIV-positive MSM.
From the Journals
Long-term entecavir looks safe, effective in HBV
The entecavir and nonentecavir trial arms did not significantly differ in time-to-event analyses of malignant neoplasms, liver-related HBV disease...
Conference Coverage
What’s new in hepatitis C: Four themes that dominated at the Liver Meeting
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy,...
Conference Coverage
ED-based HCV screening found feasible, linkage low
BOSTON – Among patients with homes, linkage to care was 59%, compared with 20% for patients who were homeless.
Conference Coverage
Hepatitis B debrief: Key themes that emerged at AASLD
BOSTON – Hot topics included HBV natural history, novel therapies, and prevention.
Conference Coverage
HVPG predicts clinical benefit after sustained virologic response
BOSTON – This provides, for the first time, firm evidence that HVPG can be taken as a surrogate endpoint for studies...
Conference Coverage
Short-course DAA therapy may prevent hepatitis transmission in transplant patients
BOSTON – While curing infection post transplant works, prevention would be preferable, investigators say.
From the Journals
Level of hepatitis B core–related antigen is risk factor for hepatocellular carcinoma
Compared with patients whose HBcrAg level was less than 10 KU/mL, a level of 10-99 KU/mL was associated with a nearly threefold increase in risk...
Conference Coverage
HDV combo therapy reduces viral loads
BOSTON – Interim results of the open-label LIFT trial show positive results after 6 months of therapy.